Skip to main content
PMC home page
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2019 Oct 25;18(6):4774–4780. doi: 10.3892/etm.2019.8132

Icariin reduces high glucose-induced endothelial progenitor cell dysfunction via inhibiting the p38/CREB pathway and activating the Akt/eNOS/NO pathway

Sisi Chen 1,2,3, Zhenya Wang 1,2,3, Heng Zhou 1,2,3, Bo He 1,2,3, Dan Hu 1,2,3, Hong Jiang 1,2,3,✉
PMCID: PMC6861942  PMID: 31772646

Abstract

High glucose (HG) impairs endothelial progenitor cell (EPC) function. The activation of p38 mitogen-activated protein kinase and the inhibition of the Akt/eNOS/NO pathway serve central roles in this process. Icariin has protective effects in endothelial cells. The aim of the present study was to investigate the effects of icariin on HG-induced EPC dysfunction, including proliferation, migration and tube formation. Experiments were performed with EPCs isolated from the femurs and tibias of Sprague-Dawley rats in vitro. In a dose-dependent manner, icariin reversed the inhibition of EPC proliferation induced by HG treatment, and the maximal effective concentration of icariin was 1 µM [Fold change (FC):0.90±0.07, P=0.0124 vs. HG group]. The impaired EPC migration and tube formation induced by glucose was partially restored by 1 µM icariin treatment (FC: 0.81±0.08, P=0.0148 vs. HG group for migration; 0.82±0.03, P=0.0214 vs. HG group for tube formation). Furthermore, icariin significantly suppressed HG-induced p38 and cAMP response element binding protein (CREB) phosphorylation in EPCs (FC: 1.84±0.21, P=0.0238 vs. HG group for p38; FC: 2.24±0.15, P=0.0068 vs. HG group for CREB). Increased Akt and endothelial nitric oxide (NO) synthase (eNOS) activation was also observed after icariin treatment (FC: 0.64±0.08, P=0.0047 vs. HG group for Akt; FC:0.53±0.05, P=0.0019 vs. HG group for eNOS), which was followed by increased NO production (FC: 0.69±0.06, P=0.0064 vs. HG group). In conclusion, icariin attenuated HG-induced EPC dysfunction, which may be partially attributed to the inhibition of the p38/CREB pathway and the activation of the Akt/eNOS/NO pathway. Icariin may be a therapeutic candidate for improving the function of EPC.

Keywords: icariin, endothelial progenitor cell, proliferation, migration, tube formation

Introduction

Endothelial progenitor cells (EPCs), derived from bone marrow or peripheral blood cells, have been shown to be incorporated into the foci of physiological and pathological neovascularization (1). EPCs can home to sites of ischemia, differentiate into endothelial cells and can contribute to postnatal neovascular formation (2). The beneficial angiogenic properties of EPC for cell therapy have attracted the attention of numerous researchers (3,4); however, the initial clinical use of EPCs has not yielded the predicted positive outcomes (5). One of the reasons is that patients with coronary artery disease (CAD) already possess risk factors, such as diabetes, hypertension and smoking, which could reduce EPC number and impair EPC migration (6). EPCs isolated from patients with type I or type II diabetes exhibited impaired proliferation, adhesion and incorporation into vascular structures (7). High glucose (HG) also impairs the number and function of EPCs (8,9). The mechanism of HG-induced EPC impairment is related to the activation of the p38 mitogen-activated protein kinase (MAPK) pathway (10). Additionally, a number of studies have shown that HG could reduce EPC proliferation and migration by exerting a deleterious effect on the PI3K/Akt/endothelial nitric oxide (NO) synthase (eNOS) signaling cascade (11,12).

Icariin (C33H40O15; molecular weight, 676.66), a flavonoid extracted from several plants in the genus Epimedium, exhibits various pharmacological activities, including enhancing immune function, stimulating osteoblast proliferation, antioxidative stress, antiapoptosis, stimulation of angiogenesis and improving cardiovascular function (13–16). Icariin has been shown to protect against endothelial cell dysfunction by activating eNOS and increasing NO production (17). However, the role of icariin in HG-induced EPC dysfunction is yet to be elucidated. In the present study, it was hypothesized that the administration of icariin could reduce glucose-induced EPC dysfunction.

Materials and methods

Cell culture and icariin treatment

Male Sprague Dawley (SD) wild-type rats (SPF grade; 180–200 g; 2–3 weeks; n=3) were obtained from Wuhan University Experiment Animal Center. These rats were allowed free access to standard rat chow and water, and were kept in an environment with controlled temperature and lighting (24°C; 12/12 h-light/dark cycle; humidity, 50–60%). Mononuclear cells were isolated from bone marrow from the femurs and tibias of SD rats, and cultured in endothelial basal medium (EBM-2 SingleQuots; Lonza Group, Ltd.) containing 5% FBS, human vascular endothelial growth factor A, human fibroblast growth factor-2, human epidermal growth factor, insulin-like growth factor-1 and ascorbic acid (EBM-2 SingleQuots; Lonza Group, Ltd.) to induce mononuclear cells differentiation into EPCs at 37°C in an atmosphere containing 95% air and 5% CO2. After 3 days in culture, the non-adherent cells were removed, and the adherent cells were maintained in new media. EPCs were characterized by FITC-Ulex europaeus agglutinin I (cat. no. L9006; Sigma-Aldrich; Merck KGaA) and DiI-acetylated low-density lipoprotein (cat. no. H7970; Beijing Solarbio Science & Technology Co., Ltd.) as previously described (18). Icariin (≥94% purity as determined by high-performance liquid chromatography analysis by the supplier) was purchased from Sigma-Aldrich (Merck KGaA) and dissolved in dimethyl sulfoxide at a concentration of 10 mmol/l for storage. The cytotoxicity of icariin toward EPC was evaluated using a cell viability assay. Following incubation of EPCs with icariin (0.01, 0.1 or 1 µM), cells were exposed to 0.4% trypan blue solution (cat. no. T6146; Sigma-Aldrich; Merck KGaA) for 5 min and viewed under a light microscope (magnification, ×100). Cell viability was defined as the ratio of unstained cells to the total number of cells. The EPCs were cultured in 5.5 mM glucose (Control group) or 25 mM glucose (HG group) for 3 days at 37°C and used for subsequent experiments (19). In the proliferation assay, the cells were cultured in serum-free EBM-2 for 12 h for synchronization and then treated with or without icariin (0.01, 0.1 or 1 µM) under a high glucose condition for 24 h. The EPCs were treated with or without icariin (1 µM) under high glucose condition for 4 h in the migration assay, for 8 h in Matrigel tube formation assay, and for 30 min in the measurement of NO production at room temperature. In the western blot analysis, the cells were stimulated with or without icariin (1 µM) under a high glucose condition for 30 min. The animal protocol in the present study was approved by the Institutional Animal Care and Use Committee, the Animal Care and Use Committee of Wuhan University (permit no. WDRM20161204).

Cell proliferation assay

Cell proliferation was assessed using a CCK-8 kit (Dojindo Molecular Technologies, Inc.). In each well of a 96-well plate, 5,000 EPCs were seeded and cultured for 12 h at 37°C in an atmosphere containing 95% air and 5% CO2. After synchronization in EBM-2 with 0.1% FBS for 12 h, the EPCs were treated with icariin at three different concentrations (0.01, 0.1 or 1 µM) for 24 h at 37°C (20). Thereafter, a total of 20 µl Cell Counting Kit-8 (CCK-8) reagent was added to each well and the cells were incubated at 37°C for a further 4 h, The absorbance at 450 nm was subsequently measured. The results are expressed as the fold change of the optical density value divided by that of the control group.

Cell migration assay

To evaluate the migratory ability of EPCs, a Transwell chamber assay (Corning, Inc.) was performed. Briefly, EPCs were seeded at a density of 5×104 cells/well in the upper chamber with serum-free EBM-2 and different stimulation conditions, and the lower chamber was filled with serum-free EBM-2 containing stromal cell-derived factor 1a (SDF-1a; 100 ng/ml). After incubation for 4 h at 37°C, the cells on the top of the filter were removed, and the migrated cells on the bottom of the filter were fixed in 95% alcohol for 30 min and stained with 0.1% crystal violet for 10 min at room temperature. Then, the cells on the filter were counted manually in at least three random selected high-power fields (magnification, ×100) in each well under a light microscope (Olympus Corporation).

Matrigel tube formation assay

A 24-well culture plate was coated with Matrigel (BD Biosciences), which was allowed to solidify for 30 min at 37°C. EPCs (5×104/well) were seeded and incubated at 37°C for 8 h. Tube formation was defined as a structure exhibiting a length four times its width. The total length of the tube formation was measured in three random fields (magnification, ×100; Olympus Corporation) per group using Adobe Photoshop CS5 software (Adobe Systems, Inc.) (21).

Measurement of NO production

NO production was measured in culture medium with a total NO assay kit (cat. no. S0023; Beyotime Institute of Biotechnology). Briefly, EPCs (density, 1×104/ml) were plated on dishes and exposed to various treatments. Then, the supernatants were collected following centrifugation (140 × g; 10 min) at room temperature and analyzed according to the manufacturer's protocol. The total NO production of EPCs was determined by measuring the concentrations of nitrate and nitrite using the Griess method, and was normalized to standards in the total NO assay kit.

Western blot assay

Cells were lysed in a RIPA lysis buffer according to the manufacturer's protocol (BioVision, Inc.). Protein concentrations were determined by a bicinchoninic acid protein assay (Beyotime Institute of Biotechnology). Proteins samples (4.5 µg/µl; 20 µl per lane) were separated using 10% SDS-PAGE and transferred onto PVDF membranes. For western blot analysis, the PVDF membranes were blocked at room temperature. with 5% non-fat dried milk that was dissolved in Tris-buffered saline containing 0.1% tween-20 for 90 min and probed with antibodies (1:1,000) against phosphorylated (p)-p38 (cat. no. sc-7973; Santa Cruz Biotechnology, Inc.), p38 (cat. no. ab7952; Abcam), protein-CREB (cat. no. 11273; Signalway Antibody LLC), CREB (cat. no. 9197; Cell Signaling Technology, Inc.), p-Akt (cat. no. 4060; Cell Signaling Technology, Inc.), Akt (cat. no. 21054; Signalway Antibody LLC), p-eNOS (cat. no. 9574; Cell Signaling Technology, Inc.), eNOS (cat. no. 21170; Signalway Antibody LLC) and GAPDH (cat. no. sc-365062; Santa Cruz Biotechnology, Inc.) overnight at 4°C. After washing three times, the membranes were incubated with peroxidase-conjugated secondary antibodies (Goat Anti Rabbit IgG/HRP; 1:50,000; cat. no. 31460; Pierce; Thermo Fisher Scientific, Inc.; Goat Anti Mouse IgG/HRP; 1:50,000; cat. no. 31430; Pierce; Thermo Fisher Scientific, Inc.) for 1 h at room temperature, and enhanced chemiluminescence (Thermo Fisher Scientific, Inc.) was performed. The autoradiographs were scanned using Adobe Photoshop CS5 software, and the protein ratios were calculated (22).

Statistical analysis

The experimental data are presented as the mean ± SD. One-way analysis of variance followed by Bonferroni post hoc test was used for comparisons between continuous variables. All statistical analyses were performed using SPSS 19.0 for Windows (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

Icariin attenuates the EPC dysfunction induced by HG

High glucose, which is a risk factor for CAD (23), significantly impaired EPC proliferation, migration and tube formation (Fig. 1). Icariin, a flavonoid extracted from genus Epimedium, exhibits various pharmacological activities (24). The differences between the HG group and icariin group were analyzed to evaluate the hypothesis that icariin could attenuate the impairment of EPC function induced by HG. Icariin had no notable effects on EPC viability (data not shown). Treatment with icariin ameliorated the inhibition of EPC proliferation in HG conditions in a dose-dependent manner in vitro, with maximal improvement observed following treatment with 1 µM icariin (Fold change: 0.64±0.07; P=0.0019 HG group vs. control group; Fold change: 0.90±0.07, P=0.0124 1 µM icariin group vs. HG group; Fig. 1A). Additionally, 1 µM icariin treatment significantly increased HG-impaired EPC migration toward SDF-1a (Fold change: 0.59±0.03; P=0.0100 HG group vs. control group; Fold change: 0.81±0.08, P=0.0148 1 µM icariin group vs. HG group; Fig. 1B and C). Furthermore, icariin improved the in vitro tube-structure formation ability of EPCs in HG-stimulated conditions (Fold change: 0.52±0.06; P=0.0070 HG group vs. control group; Fold change: 0.82±0.03, P=0.0214; 1 µM icariin group vs. HG group; Fig. 1D and E).

Figure 1.

Figure 1.

Open in a new tab

Icariin rescues the EPC dysfunction induced by HG. (A) EPCs were treated with various concentrations of icariin for 24 h in HG conditions. Cell proliferation was determined by a Cell Counting Kit-8 assay. (B) EPCs were treated with or without 1 µM icariin in Transwell plates for 4 h. The migrated cells were counted under an optical microscope. (C) The relative levels of EPC migration. (D) EPCs cultured on a layer of Matrigel were treated with or without 1 µM icariin. The total length of the tube formation was measured in three random fields. for each group. (E) The relative levels of EPC tube formation. Data are presented as the mean ± SD of three individual experiments. *P<0.05 vs. Control group, #P<0.05 vs. HG group. EPC, endothelial progenitor cell; HG, high glucose.

Icariin inhibits the HG-induced activation of p38 and CREB

p38 and its downstream target CREB have been reported to play a critical role in EPC downregulation induced by HG (25). Consistent with this previous study, increased p38 and CREB phosphorylation levels were observed in EPCs cultured in 25 mM glucose for 3 days. These effects were significantly inhibited by icariin (1 µM, 30 min), and the treatments did not notably alter total p38 and CREB expression levels (p38 phosphorylation: Fold change: 2.38±0.17; P=0.0005 HG group vs. control group; Fold change: 1.84±0.21; P=0.0238 icariin group vs. HG group; CREB phosphorylation: Fold change: 3.04±0.22; P=0.0002 HG group vs. control group; Fold change: 2.24±0.15, P=0.0068 icariin group vs. HG group; Fig. 2).

Figure 2.

Figure 2.

Open in a new tab

Icariin inhibits the HG-induced phosphorylation of p38 and CREB in EPCs. (A) EPCs cultured in 5.5 (Control) or 25 mM glucose (HG) were treated with or without 1 µM icariin for 30 min. Levels of p-p38, total p38, p-CREB and total CREB were determined via western blot analysis. (B) Quantitative results of the phosphorylated levels of p38. (C) Quantitative results of the phosphorylated levels of CREB. Data are presented as the mean ± SD; n=3/group. *P<0.05 vs. Control group, #P<0.05 vs. HG group. CREB, cAMP response element binding protein; EPC, endothelial progenitor cell; HG, high glucose; p-, phosphorylated.

Icariin activates Akt and eNOS, and promotes NO production in HG-treated EPCs

It has been reported that the inhibitory effects of HG on Akt and eNOS phosphorylation are involved in HG-induced EPC dysfunction (11). The effects of icariin on Akt and eNOS phosphorylation were determined via western blot analysis. Icariin treatment increased significantly Akt and eNOS phosphorylation compared with HG treatment only (Akt phosphorylation: Fold change: 0.29±0.07; P=0.0016 HG group vs. control group; Fold change: 0.64±0.08; P=0.0047 icariin group vs. HG group; eNOS phosphorylation: Fold change: 0.24±0.05; P<0.0001 HG group vs. control group; Fold change: 0.53±0.05, P=0.0019 icariin group vs. HG group; Fig. 3A-C). Furthermore, icariin significantly attenuated the HG-induced inhibition of NO production (Fold change: 0.48±0.03; P<0.0001 HG group vs. control group; Fold change: 0.69±0.06; P=0.0064 icariin group vs. HG group; Fig. 3D).

Figure 3.

Figure 3.

Open in a new tab

Icariin induces Akt and eNOS phosphorylation, and NO production in HG-treated EPCs. (A) EPCs were cultured in 5.5 (Control) or 25 mM glucose (HG) for 3 days with or without treatment with 1 µM icariin for 30 min. Levels of p- and total Akt and eNOS were determined via western blot analysis. (B) Quantitative results of the phosphorylated levels of Akt (C) Quantitative results of the phosphorylated levels of eNOS (D) EPCs were treated with or without 1 □M icariin for 3 h. The relative levels of intracellular NO were determined by the concentrations of nitrate and nitrite. Data are presented as the mean ± SD; n=3/group. *P<0.05 vs. Control group, #P<0.05 vs. HG group. eNOS, endothelial nitric oxide synthase; EPC, endothelial progenitor cell; HG, high glucose; NO, nitric oxide; p-, phosphorylated.

Discussion

The present study demonstrated that icariin could ameliorate the inhibition of EPC proliferation, migration and tube formation induced by HG. Additionally, icariin significantly reduced the activation of the p38/CREB pathway and stimulated the Akt/eNOS/NO pathway in EPCs treated with HG. These results indicated potential mechanisms underlying the protective effects of icariin on EPCs, and suggested that icariin may be a useful agent for improving EPC function in a HG microenvironment.

Previous studies reported that icariin exerts endothelial protection effects (17,26). Icariin stimulated human umbilical vein endothelial cell proliferation, migration (27) and NO release (28). Icariin also delayed homocysteine-induced senescence (27) and inhibited oxidation-induced apoptosis (29). However, the effects of icariin on EPC function remain unclear. Numerous clinical trials are attempting to elucidate the therapeutic effects of EPCs in cardiovascular diseases, but the CAD risk factors that may reduce the number and biological activity of EPC limit the success of EPC transplantation in patients (6,30). Therefore, this study focused mainly on the effects of icariin on EPCs under HG conditions, which is one of the major CAD risk factors (23). HG has been shown to adversely affect the number and function of EPCs, leading to reductions in the angiogenic abilities of EPCs (31). Consistent with the current study, the present data demonstrated that incubation with HG induces adverse effects on EPC function. Of note, the present findings showed that icariin treatment attenuates HG-induced EPC dysfunction.

Several mechanisms may be involved in the HG-induced reduction in EPC number, and impairment in EPC proliferative and migratory abilities. p38 MAPK and its downstream target CREB have been shown to decrease the number and proliferation of EPCs (25). HG induced the p38-dependent phosphorylation of CREB, thereby inhibiting proliferation (25). As icariin has been reported to modulate p38 phosphorylation in other cell types (32,33), this may be a potential effector signaling mechanism via which icariin attenuated the impaired proliferation of HG-treated EPCs. In the present study, p38 and CREB were demonstrated to be phosphorylated under high glucose conditions, and icariin could reduce these effects.

Another important mechanism involved with HG-induced impairments in EPC migration is the inhibition of PI3K/Akt/eNOS activation and NO production (11), suggesting that the effects of icariin on Akt/eNOS may ameliorate this dysfunction. Icariin is also known to stimulate angiogenesis by activating PI3K/Akt/eNOS-dependent signaling pathways in human endothelial cells (28). Akt/eNOS activation is also known to increase NO activation (34), and NO is known to regulate the migration of EPCs (35). The restored migration induced by icariin may be due to upregulated Akt/eNOS phosphorylation and NO production. In the present study, it was demonstrated that high glucose could inhibit the phosphorylation of Akt/eNOS and the production of NO, and these effects were significantly attenuated by icariin.

There are certain limitations to the present study. Only in vitro experiments were performed to show that icariin could reduce HG-induced EPC dysfunction. EPC function in HG microenvironments was only evaluated in vitro, while the damage produced by HG in humans is observed after several years in vivo. Although the present study may provide a certain degree of insight into the mechanisms involved in vivo, further study in vivo is required to clarify the exact mechanisms. Additionally, gene silencing technology could be employed to further demonstrate the exact role of the p38/CREB and Akt/eNOS signaling pathways in the effects induced by icariin.

Collectively, the results of the present study demonstrated that icariin can attenuate HG-induced EPC dysfunction in vitro, including improving proliferation, migration and tube formation. Furthermore, the possible molecular mechanisms involved were identified as the inhibited activation of the p38/CREB signaling pathway and the promotion of the Akt/eNOS/NO signaling pathway (Fig. 4). Therefore, icariin may be a potentially promising tool for protecting EPC function against HG.

Figure 4.

Figure 4.

Open in a new tab

Schematic of the potential role and mechanisms of icariin in HG-induced EPC dysfunction. Icariin can inhibit the activation of the p38/CREB signaling pathway induced by HG in EPCs, and activate the Akt/eNOS/NO signaling pathway that is inhibited by HG in EPCs. It is proposed that via these mechanisms, icariin attenuates HG-induced EPC dysfunction. CREB, cAMP response element binding protein; eNOS, endothelial nitric oxide synthase; EPC, endothelial progenitor cell; HG, high glucose; NO, nitric oxide; p-, phosphorylated.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81600226).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

HJ designed and directed the experiments. SC, ZW and HZ performed the experiments. SC, ZW, HB and DH collected and analyzed the experimental data. SC and HJ wrote the manuscript. HZ and HB investigated the relevant literature and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by Institutional Animal Care and Use Committee, the Animal Care and Use Committee of Wuhan University (permit no. WDRM20161204).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221–228. doi: 10.1161/01.RES.85.3.221. [DOI] [PubMed] [Google Scholar]
  • 2.Jin P, Li T, Li X, Shen X, Zhao Y. Suppression of oxidative stress in endothelial progenitor cells promotes angiogenesis and improves cardiac function following myocardial infarction in diabetic mice. Exp Ther Med. 2016;11:2163–2170. doi: 10.3892/etm.2016.3236. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 3.Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1–11. doi: 10.1016/j.jacc.2013.09.019. [DOI] [PubMed] [Google Scholar]
  • 4.Odent Grigorescu G, Preda MB, Radu E, Rosca AM, Tutuianu R, Mitroi DN, Simionescu M, Burlacu A. Combinatorial approach for improving the outcome of angiogenic therapy in ischemic tissues. Biomaterials. 2015;60:72–81. doi: 10.1016/j.biomaterials.2015.05.002. [DOI] [PubMed] [Google Scholar]
  • 5.Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol. 2007;49:741–752. doi: 10.1016/j.jacc.2006.09.050. [DOI] [PubMed] [Google Scholar]
  • 6.Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–E7. doi: 10.1161/hh1301.093953. [DOI] [PubMed] [Google Scholar]
  • 7.Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, Tiengo A, Agostini C, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26:2140–2146. doi: 10.1161/01.ATV.0000237750.44469.88. [DOI] [PubMed] [Google Scholar]
  • 8.Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449–1457. doi: 10.1016/j.jacc.2004.11.067. [DOI] [PubMed] [Google Scholar]
  • 9.Tsukada S, Masuda H, Jung SY, Yun J, Kang S, Kim DY, Park JH, Ji ST, Kwon SM, Asahara T. Impaired development and dysfunction of endothelial progenitor cells in type 2 diabetic mice. Diabetes Metab. 2017;43:154–162. doi: 10.1016/j.diabet.2016.07.034. [DOI] [PubMed] [Google Scholar]
  • 10.Chang J, Li Y, Huang Y, Lam KS, Hoo RL, Wong WT, Cheng KK, Wang Y, Vanhoutte PM, Xu A. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes. 2010;59:2949–2959. doi: 10.2337/db10-0582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sun N, Wang H, Wang L. Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. Int J Clin Exp Pathol. 2015;8:482–489. [PMC free article] [PubMed] [Google Scholar]
  • 12.Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL, Chen JW. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes. 2007;56:1559–1568. doi: 10.2337/db06-1103. [DOI] [PubMed] [Google Scholar]
  • 13.Shen R, Wang JH. The effect of icariin on immunity and its potential application. Am J Clin Exp Immunol. 2018;7:50–56. [PMC free article] [PubMed] [Google Scholar]
  • 14.Jin J, Wang H, Hua X, Chen D, Huang C, Chen Z. An outline for the pharmacological effect of icariin in the nervous system. Eur J Pharmacol. 2019;842:20–32. doi: 10.1016/j.ejphar.2018.10.006. [DOI] [PubMed] [Google Scholar]
  • 15.Wang Z, Wang D, Yang D, Zhen W, Zhang J, Peng S. The effect of icariin on bone metabolism and its potential clinical application. Osteoporos Int. 2018;29:535–544. doi: 10.1007/s00198-017-4255-1. [DOI] [PubMed] [Google Scholar]
  • 16.Qian ZQ, Wang YW, Li YL, Li YQ, Ling-Zhu, Yang DL. Icariin prevents hypertension-induced cardiomyocyte apoptosis through the mitochondrial apoptotic pathway. Biomed Pharmacother. 2017;88:823–831. doi: 10.1016/j.biopha.2017.01.147. [DOI] [PubMed] [Google Scholar]
  • 17.Xu HB, Huang ZQ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol. 2007;47:18–24. doi: 10.1016/j.vph.2007.03.002. [DOI] [PubMed] [Google Scholar]
  • 18.Song E, Lu CW, Fang LJ, Yang W. Culture and identification of endothelial progenitor cells from human umbilical cord blood. Int J Ophthalmol. 2010;3:49–53. doi: 10.3980/j.issn.2222-3959.2010.01.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A. Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res. 2010;126:166–174. doi: 10.1016/j.thromres.2010.03.002. [DOI] [PubMed] [Google Scholar]
  • 20.Koizumi H, Yu J, Hashimoto R, Ouchi Y, Okabe T. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Lett. 2010;584:2440–2444. doi: 10.1016/j.febslet.2010.04.049. [DOI] [PubMed] [Google Scholar]
  • 21.Ma FX, Chen F, Ren Q, Han ZC. Lovastatin restores the function of endothelial progenitor cells damaged by oxLDL. Acta Pharmacol Sin. 2009;30:545–552. doi: 10.1038/aps.2009.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Cheng L, Xu J, Qian YY, Pan HY, Yang H, Shao MY, Cheng R, Hu T. Interaction between mDia1 and ROCK in Rho-induced migration and adhesion of human dental pulp cells. Int Endod J. 2017;50:15–23. doi: 10.1111/iej.12587. [DOI] [PubMed] [Google Scholar]
  • 23.Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J. 2015;36:1454–1462. doi: 10.1093/eurheartj/ehv083. [DOI] [PubMed] [Google Scholar]
  • 24.Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci. 2015;126:57–68. doi: 10.1016/j.lfs.2015.01.006. [DOI] [PubMed] [Google Scholar]
  • 25.Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, Rössig L, Corbaz A, Chvatchko Y, Zeiher AM, et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation. 2005;111:1184–1191. doi: 10.1161/01.CIR.0000157156.85397.A1. [DOI] [PubMed] [Google Scholar]
  • 26.Xiao HB, Liu ZK, Lu XY, Deng CN, Luo ZF. Icariin regulates PRMT/ADMA/DDAH pathway to improve endothelial function. Pharmacological reports: PR. 2015;67:1147–1154. doi: 10.1016/j.pharep.2015.04.017. [DOI] [PubMed] [Google Scholar]
  • 27.Xiao-Hong D, Chang-Qin X, Jian-Hua H, Wen-Jiang Z, Bing S. Icariin delays homocysteine-induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway. Pharm Biol. 2013;51:433–440. doi: 10.3109/13880209.2012.738332. [DOI] [PubMed] [Google Scholar]
  • 28.Chung BH, Kim JD, Kim CK, Kim JH, Won MH, Lee HS, Dong MS, Ha KS, Kwon YG, Kim YM. Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun. 2008;376:404–408. doi: 10.1016/j.bbrc.2008.09.001. [DOI] [PubMed] [Google Scholar]
  • 29.Song YH, Cai H, Zhao ZM, Chang WJ, Gu N, Cao SP, Wu ML. Icariin attenuated oxidative stress induced-cardiac apoptosis by mitochondria protection and ERK activation. Biomed Pharmacother. 2016;83:1089–1094. doi: 10.1016/j.biopha.2016.08.016. [DOI] [PubMed] [Google Scholar]
  • 30.Wang HY, Gao PJ, Ji KD, Shen WF, Fan CL, Lu L, Zhu DL. Circulating endothelial progenitor cells, C-reactive protein and severity of coronary stenosis in Chinese patients with coronary artery disease. Hypertension Research: Official Journal of the Japanese Society of Hypertension. 2007;30:133–141. doi: 10.1291/hypres.30.133. [DOI] [PubMed] [Google Scholar]
  • 31.Huang PH, Chen JW, Lin CP, Chen YH, Wang CH, Leu HB, Lin SJ. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions. Cardiovasc Diabetol. 2012;11:99. doi: 10.1186/1475-2840-11-99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ding L, Liang XG, Hu Y, Zhu DY, Lou YJ. Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro. Stem Cells Dev. 2008;17:751–760. doi: 10.1089/scd.2007.0206. [DOI] [PubMed] [Google Scholar]
  • 33.Qin S, Zhou W, Liu S, Chen P, Wu H. Icariin stimulates the proliferation of rat bone mesenchymal stem cells via ERK and p38 MAPK signaling. Int J Clin Exp Med. 2015;8:7125–7133. [PMC free article] [PubMed] [Google Scholar]
  • 34.Taguchi K, Hida M, Hasegawa M, Matsumoto T, Kobayashi T. Dietary polyphenol morin rescues endothelial dysfunction in a diabetic mouse model by activating the Akt/eNOS pathway. Mol Nutr Food Res. 2016;60:580–588. doi: 10.1002/mnfr.201500618. [DOI] [PubMed] [Google Scholar]
  • 35.Hamed S, Brenner B, Roguin A. Nitric oxide: A key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res. 2011;91:9–15. doi: 10.1093/cvr/cvq412. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES